Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Surprising study findings from a look at refrigerator temperatures and the risk posed to insulin quality; plus, a guide to safe insulin storage and Med Angel’s very cool...
Insightful diabetes leaders discuss high-potential areas ranging from SGLT-2s in type 1 diabetes, personalized treatment plans, and the do-it-yourself Loop app
Zealand Pharma shared positive trial results for its dasiglucagon – 99% of participants recovered from hypo within 15 minutes of treatment
The benefits of measuring time in range, plus new care guidelines for adults with type 2 diabetes
A new guidance document from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) calls for more patient-centered care and...
Amarin’s Vascepa, an omega-3 fatty acid, is shown to lower risk of heart attack, stroke, and heart-related death for adults with high risk for heart disease with...
Heart benefits of the SGLT-2 inhibitor pill beyond blood sugars and weight loss for people with type 2 diabetes
CGM data in people without diabetes, time-in-range and A1C benefits in large hybrid closed loop study, plus trial results studying Jardiance in type 1 as well as Lilly’s...
SGLT-1/2 therapy for type 1 diabetes, hybrid closed loop systems in teens and children, and the importance of glucose control as an outcome in addition to A1C!
The most promising therapies in the pipeline, accuracy data on the FreeStyle Libre 2, and more
A study is enrolling over 100 people with type 2 between the ages of 10 and 18 years, examining Jardiance and Tradjenta
A new study will investigate whether SGLT-2 inhibitor Farxiga can delay the progression of heart failure in people with and without type 2 diabetes
Xeris’ Glucagon Rescue Pen, designed as an auto-injector, features a ready-to-use liquid glucagon – a safer and more convenient treatment option for severe hypoglycemia
A study recruiting 10,000 people will look at whether Zynquista (sotagliflozin) has effects beyond glucose-lowering and weight loss
If approved, Lilly’s intranasal glucagon would be a radical ease-of-use improvement over current glucagon kits for severe hypoglycemia
The diaTribe Foundation and TCOYD hosted a panel discussion at the ADA 78 th Scientific Sessions in Orlando, Florida; read about insights on how to improve diabetes care
The results were so positive it was deemed unethical to keep giving people placebo instead of Invokana, an SGLT-2 inhibitor approved for type 2 diabetes
A new study is investigating whether higher doses of injectable GLP-1 agonist Trulicity (dulaglutide) are more effective; it is recruiting 1,800 participants with type 2...
U500 insulin delivery through Omnipod pump, comparing insulin secretion between Mediterranean and ketogenic meals, a head-to-head with Afrezza and NovoLog, Qtern...
Using time-in-range to assess risk for complications, Omnipod Horizon Closed Loop, Bihormonal closed loop (insulin + Pramlintide), SGLT-2 oral drug for type 1, and more!

Pages